[Reporter’s Notebook] The US Seeks Allies, China Arms Itself with Data, and Korea Stands in Between
The landscape of the global pharmaceutical and biotech industry exhibition ‘Bio International Convention (Bio USA),’ currently being held in San Diego, United States, has changed dramatically this year. The booths of Chinese companies have noticeably decreased, with U.S. state government pavilions now filling the vacant spots. This is a result of the supply chain reorganization that became visible after the enactment of the U.S. Biosecurity Law. Just two years ago, Chinese global contract development and manufacturing organization (CDMO) companies occupied prime locations, but they have now disappeared. Members of the National Security Commission on Emerging Biotechnology (NSCEB), the Administration for Strategic Preparedness and Response (ASPR), and the Advanced Research Projects Agency for Health (ARPA-H), all under the U.S. Congress, conveyed a unified message on stage: “The United States cannot rebuild the bio supply chain alone.” The world’s leading biotechnology power has acknowledged its own limitations and is reaching out to its allies.
But how many countries are truly ready to take that hand? The ‘distributed bio-manufacturing system’ envisioned by the United States is not simply about outsourcing production. NSCEB, in one of its six recommendations, suggested ‘maximizing biotechnology cooperation with allied countries’ and even recommended establishing a National Bio Coordination Office within the White House, in an effort to systematize cooperation channels with allies. Dr. John Siel of ARPA-H stated that while the United States aims to secure core technologies domestically in the long term, it also seeks partners to collaborate with from the design stage. New partnership models were discussed, such as joint procurement, sharing of research data, and inter-university collaboration. India is already being incorporated into the U.S. supply chain reorganization plan due to its active pharmaceutical ingredient (API) manufacturing capabilities, and Mexico is included thanks to its geographic proximity and division of labor structure. Now, it is time for Korea to urgently determine where it will position itself within this new framework.
The problem is that Korea’s hand of cards may be thinner than expected. Lee Seung-kyou, Vice Chairman of the Korea Biotechnology Industry Organization (KoreaBIO), did not conceal his warning at the on-site press briefing. The number of pipelines in China has already reached three-quarters that of the United States, and Chinese firms are attracting investment from multinational pharmaceutical companies by leveraging validated data from phase 2 and above clinical trials. While capital is flowing into Chinese companies equipped with solid proof-of-concept (PoC) data, Korean companies remain stuck at the preclinical stage, facing barriers to financing as they try to move into clinical trials. “With very little investment recently, it has become extremely difficult to progress to clinical stages and conduct proof-of-concept trials,” Lee lamented. Korea’s strengths in the CDMO sector alone are not enough to become the ‘design partner’ the United States desires, and the nation faces dual pressure as it falls behind China in the competition for pipelines. Now that the United States has opened its doors to allies, Korea must honestly assess whether it is truly prepared to walk through those doors.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
There are, however, some encouraging signals. This year at Bio USA, eight organizations, including KOTRA, collaborated to establish the largest-ever integrated Korean pavilion, featuring 79 companies. Even more noteworthy is the fact that the official ‘Korea Session’—the first ever to discuss the growth of the Asian market in the history of Bio USA—was held. The fact that the organizers, the Biotechnology Innovation Organization (BIO), proactively put Korea on the agenda is proof that Korea’s standing in the global bio ecosystem has risen significantly. As Lee Seung-kyou described, if this is indeed the ‘golden time,’ what is needed is not just a show of presence through the scale of the exhibition. Instead, Korea requires funding to support phase 2 clinical trials, targeted support for ventures to swiftly complete proof-of-concept, and decisive policies to go beyond CDMO and emerge as a true technology partner. It has been confirmed that Korea is being called upon. Now, only one question remains: Are we ready?
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.